polysorbates

Summary

Summary: Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.

Top Publications

  1. ncbi Physical characterizations of microemulsion systems using tocopheryl polyethylene glycol 1000 succinate (TPGS) as a surfactant for the oral delivery of protein drugs
    Wen Ting Ke
    Graduate Institute of Pharmaceutical Sciences, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC
    J Control Release 102:489-507. 2005
  2. ncbi Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants
    Gamal M El Maghraby
    Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, P O Box 2457, Saudi Arabia
    Int J Pharm 355:285-92. 2008
  3. ncbi Nanoparticulate systems for brain delivery of drugs
    J Kreuter
    Institut fur Pharmazeutische Technologie, Biozentrum, J W Goethe Universitat, D 60439 Frankfurt, Germany
    Adv Drug Deliv Rev 47:65-81. 2001
  4. ncbi Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study
    Terho Heikkinen
    Department of Pediatrics, University of Turku, Turku, Finland
    Am J Obstet Gynecol 207:177.e1-8. 2012
  5. ncbi Characterization and antimicrobial activity of a pharmaceutical microemulsion
    Hui Zhang
    Department of Food Science and Nutrition, Huajiachi Campus, Zhejiang University, Hangzhou 310029, China
    Int J Pharm 395:154-60. 2010
  6. pmc Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine
    Hee Jin Cheong
    Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 97 Gurodong Gil, Guro Gu, Seoul 152 703, South Korea
    Clin Vaccine Immunol 18:1358-64. 2011
  7. ncbi The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
    Anja Seubert
    Novartis Vaccines, Siena, Italy
    J Immunol 180:5402-12. 2008
  8. ncbi Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects
    Hiroyuki Fukase
    CPC Clinic, Medipolis Medical Research Institute, Kagoshima, Japan
    Vaccine 30:5030-7. 2012
  9. pmc Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins
    Ranjit Ray
    Department of Internal Medicine and Vaccine and Treatment Evaluation Unit, Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 202:862-6. 2010
  10. ncbi Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
    Samuele Calabro
    Novartis Vaccines and Diagnostics, Siena, Italy
    Vaccine 29:1812-23. 2011

Detail Information

Publications229 found, 100 shown here

  1. ncbi Physical characterizations of microemulsion systems using tocopheryl polyethylene glycol 1000 succinate (TPGS) as a surfactant for the oral delivery of protein drugs
    Wen Ting Ke
    Graduate Institute of Pharmaceutical Sciences, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC
    J Control Release 102:489-507. 2005
    ..of Captex 300 and water with D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) as main surfactant, polysorbates (Tween 20, Tween 40, Tween 60 and Tween 80) as adjuvant surfactants, and polyethylene glycols (PEG 400 and PEG ..
  2. ncbi Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants
    Gamal M El Maghraby
    Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, P O Box 2457, Saudi Arabia
    Int J Pharm 355:285-92. 2008
    ..Ethanol produced the greatest effect followed by propylene glycol and isopropanol. The presence of cosurfactant and its type can thus affect both the phase behavior and the transdermal delivery potential of microemulsion...
  3. ncbi Nanoparticulate systems for brain delivery of drugs
    J Kreuter
    Institut fur Pharmazeutische Technologie, Biozentrum, J W Goethe Universitat, D 60439 Frankfurt, Germany
    Adv Drug Deliv Rev 47:65-81. 2001
    ..Nanoparticle-mediated drug transport to the brain depends on the overcoating of the particles with polysorbates, especially polysorbate 80...
  4. ncbi Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study
    Terho Heikkinen
    Department of Pediatrics, University of Turku, Turku, Finland
    Am J Obstet Gynecol 207:177.e1-8. 2012
    ..The 2009-2010 A/H1N1 pandemic provided a unique setting to study the safety of MF59-adjuvanted vaccination in pregnancy...
  5. ncbi Characterization and antimicrobial activity of a pharmaceutical microemulsion
    Hui Zhang
    Department of Food Science and Nutrition, Huajiachi Campus, Zhejiang University, Hangzhou 310029, China
    Int J Pharm 395:154-60. 2010
    ....
  6. pmc Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine
    Hee Jin Cheong
    Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 97 Gurodong Gil, Guro Gu, Seoul 152 703, South Korea
    Clin Vaccine Immunol 18:1358-64. 2011
    ..75-μg, MF59 adjuvanted vaccine priming schedule. Following a two-dose priming schedule, the increase in hemagglutinin inhibition titers was higher with MF59 adjuvanted vaccine than with nonadjuvanted vaccine...
  7. ncbi The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
    Anja Seubert
    Novartis Vaccines, Siena, Italy
    J Immunol 180:5402-12. 2008
    ....
  8. ncbi Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects
    Hiroyuki Fukase
    CPC Clinic, Medipolis Medical Research Institute, Kagoshima, Japan
    Vaccine 30:5030-7. 2012
    ....
  9. pmc Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins
    Ranjit Ray
    Department of Internal Medicine and Vaccine and Treatment Evaluation Unit, Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 202:862-6. 2010
    ..Neutralizing serum samples had increased affinity levels and displayed >2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2...
  10. ncbi Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
    Samuele Calabro
    Novartis Vaccines and Diagnostics, Siena, Italy
    Vaccine 29:1812-23. 2011
    ..Further studies will reveal whether other single cell types are crucial or whether the different recruited cell populations are redundant with overlapping functions...
  11. pmc MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults
    Angelika Banzhoff
    Novartis Vaccines, Marburg, Germany
    PLoS ONE 4:e4384. 2009
    ..Pathogenic avian influenza virus (H5N1) has the potential to cause a major global pandemic in humans. Safe and effective vaccines that induce immunologic memory and broad heterotypic response are needed...
  12. pmc Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
    Sharon E Frey
    Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, St Louis, MO 63104, USA
    Vaccine 28:6367-73. 2010
    ..We describe the first in humans clinical trial of this prophylactic HCV vaccine...
  13. ncbi MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database
    Michele Pellegrini
    Global Clinical Research and Development, Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Vaccine 27:6959-65. 2009
    ..Adding adjuvants such as MF59((R)) to influenza vaccines can enhance the immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+)MF59] compared with non-adjuvanted [(-)MF59] vaccines in a large clinical database...
  14. ncbi A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis
    Angelika Banzhoff
    Clinical Research and Medical Affairs, Chiron Vaccines, Marburg, Germany
    Gerontology 49:177-84. 2003
    ..The elderly are at a higher risk of morbidity and mortality associated with influenza infection than younger adults, but get less protection from conventional vaccination...
  15. ncbi MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Expert Rev Vaccines 6:699-710. 2007
    ..MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types...
  16. ncbi Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application
    Wim Weyenberg
    Laboratory of Pharmaceutical Technology and Biopharmacy, University of Antwerp, Universiteitsplein 1, B 2610 Antwerp, Belgium
    Int J Pharm 337:291-8. 2007
    ..Survival of macrophages was highly affected by stearic acid and stearylamine. In general a viability of more than 90% was observed when semi-synthetic glycerides or hard fat was employed to formulate nanoparticles...
  17. ncbi Composition analysis of two batches of polysorbate 60 using MS and NMR techniques
    Hoang Vu Dang
    Department of Pharmaceutical Sciences, Strathclyde Institution of Biomedical Sciences, University of Strathclyde, Glasgow, UK
    J Pharm Biomed Anal 40:1155-65. 2006
    ..1)H NMR could provide a simple and rapid pharmacopoeial test for the ratio of sorbitan to isosorbide in Tweens...
  18. ncbi Drug solubilization and in vitro toxicity evaluation of lipoamino acid surfactants
    Nathalie Ménard
    Technologie Servier, 25 27 rue Eugéne Vignat, 45000 Orléans, France
    Int J Pharm 423:312-20. 2012
    ..Although these solubilizers are promising, a compromise between drug solubilization and toxicity remains to be found...
  19. ncbi MF59 adjuvant: the best insurance against influenza strain diversity
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Expert Rev Vaccines 10:447-62. 2011
    ....
  20. ncbi Preparation and evaluation of SEDDS and SMEDDS containing carvedilol
    Lanlan Wei
    Department of Pharmaceutics, Shen Yang Pharmaceutical University, Shen Yang, P R China
    Drug Dev Ind Pharm 31:785-94. 2005
    ..The developed SEDDS formulations significantly improved the oral bioavailability of carvedilol significantly, and the relative oral bioavailability of SEDDS compared with commercially available tablets was 413%...
  21. ncbi An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 29:266-73. 2010
    ..A rapid induction of protective antibody is important in reducing community spread of pandemic influenza and in helping maintain the integrity of the health care system during the pandemic...
  22. ncbi Combined effect of pH and polysorbates with cyclodextrins on solubilization of naringenin
    S Tommasini
    Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita di Messina, Viale Annunziata, 98168 Messina, Italy
    J Pharm Biomed Anal 36:327-33. 2004
    ..Moreover, the presence of non-ionic surfactants in the media of complexation gives a positive contribution to the improvement of the solubility of naringenin, alone or in combination with beta-cyclodextrin...
  23. ncbi Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles
    Barnabas Wilson
    Department of Pharmaceutics, J S S College of Pharmacy, Ootacamund, Tamil Nadu, India
    Eur J Pharm Biopharm 70:75-84. 2008
    ..In conclusion, the present study demonstrates that the brain concentration of intravenously injected tacrine can be enhanced by binding to poly(n-butylcyanoacrylate) nanoparticles, coated with 1% the nonionic surfactant polysorbate 80...
  24. ncbi Antimicrobial activity of a food-grade fully dilutable microemulsion against Escherichia coli and Staphylococcus aureus
    Hui Zhang
    Department of Food Science and Nutrition, Huajiachi Campus, Zhejiang University, Hangzhou 310029, China
    Int J Food Microbiol 135:211-5. 2009
    ..This work suggests the potential use of food-grade fully dilutable microemulsions for antimicrobial purposes in beverages or seafood products...
  25. pmc Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
    Grazia Galli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Proc Natl Acad Sci U S A 106:3877-82. 2009
    ..We suggest that CD4(+) T cell priming might be used as an early predictor of the immunogenicity of prepandemic vaccines...
  26. ncbi Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model
    Chun Xia Wang
    Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, PR China
    Brain Res 1261:91-9. 2009
    ..05). Taken together, 1% polysorbate-80 coated GCTB-PBCA-NPs can effectively inhibit the growth of C6 glioma cells in vitro and enhance antitumor activity on brain tumor in vivo...
  27. ncbi Certain surfactants show promise in the therapy of pulmonary tuberculosis
    James K Stoops
    UT Houston Medical School, 6431 Fannin St, Houston, TX 77030, USA
    In Vivo 24:687-94. 2010
    ..This protective barrier was removed by exposing the bacteria to certain surfactants...
  28. ncbi Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC
    E Gonzalez-Mira
    Department of Physical Chemistry, Faculty of Pharmacy, Institute of Nanoscience and Nanotechnology, University of Barcelona, Av Joan XXIII s n, 08028 Barcelona, Spain
    Colloids Surf B Biointerfaces 81:412-21. 2010
    ..The developed systems were shown physico-chemically stable with high tolerance for eye instillation...
  29. ncbi Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles
    Kepan Gao
    Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, PR China
    Int J Pharm 310:213-9. 2006
    ..In conclusion, polysorbate 80-coated polybutylcyanoacrylate nanoparticles could be used to overcome blood brain barrier especially those whose diameter was below 100 nm...
  30. ncbi Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection
    Filippo Ansaldi
    Department of Health Sciences, University of Genoa CIRI IV, Inter University Research Centre on Influenza, Via Pastore 1, 16132 Genoa, Italy
    Vaccine 27:3345-8. 2009
    ..Promising results were obtained using a new generation of oil-in-water emulsion adjuvants, named AS, offering cross-protection against heterologous challenge in ferrets...
  31. pmc Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England
    Nick Andrews
    Statistics Unit, Hepatitis, and Blood Safety Department, Health Protection Agency Centre for Infections, London, England
    J Infect Dis 203:32-9. 2011
    ..The use of a squalene-containing (AS03) pandemic vaccine for high-risk groups in England allowed vaccine effectiveness (VE) of such novel oil-in-water adjuvanted vaccine to be evaluated...
  32. ncbi Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects
    R Gasparini
    Department of Health Sciences, Genoa University, Genoa, Italy
    Int J Clin Pract 64:432-8. 2010
    ..We investigated prior seasonal vaccination in adult and elderly subjects, and concomitant vaccination with seasonal vaccine in adults, on the tolerability and immunogenicity of the Novartis MF59-adjuvanted H1N1v vaccine, Focetria...
  33. ncbi In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy
    Zhiping Zhang
    Department of Chemical and Biomolecular Engineering and Division of Bioengineering, Faculty of Engineering, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260
    Biomacromolecules 7:1139-46. 2006
    ..8 +/- 4.2% for PLA-Tween 80-10 and 12.0 +/- 5.4% for PLA-Tween 80-20 copolymer nanoparticles, which was comparable with that for Taxol at the same 50 microg/mL drug concentration...
  34. ncbi The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
    A Podda
    Clinical Research and Medical Affairs, Chiron Vaccines, Chiron SpA, Via Florentina 1, 53100, Siena, Italy
    Vaccine 19:2673-80. 2001
    ..In conclusion, the addition of MF59 to subunit influenza vaccines enhances significantly the immune response in elderly subjects without causing clinically important changes in the safety profile of the influenza vaccine...
  35. ncbi MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
    Hana El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Vaccines 9:1135-41. 2010
    ..Currently, MF59 is under evaluation as an adjuvant with other antigens such as pandemic influenza antigens and cytomegalovirus antigens...
  36. ncbi Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis
    Steven Black
    Center for Global Health and Division of Infectious Diseases, Cincinnati Children s Hospital, 3333 Burnet Ave, Cincinnati, OH 45326, USA
    Vaccine 28:7331-6. 2010
    ..These data support the safety of MF59-adjuvanted influenza vaccines in the pediatric population...
  37. ncbi Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
    ..The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority...
  38. ncbi Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system
    Jyh Ding Wei
    Department of Orthopedics, Shin Kong Wu Ho Su Memorial Hospital, 95 Wenchang Road School of Pharmacy, College of Pharmacy, Taipei, Taiwan
    J Pharm Pharmacol 62:1685-96. 2010
    ..This study attempted to characterise the in-vitro release profiles of fenofibrate (FFB) from a self-microemulsifying drug-delivery system (SMEDDS) for optimising formulation factors and dissolution conditions for in-vivo absorption...
  39. ncbi Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease
    Barnabas Wilson
    Department of Pharmaceutics, J S S College of Pharmacy, Rocklands, Ootacamund, Tamil Nadu 643001, India
    Brain Res 1200:159-68. 2008
    ..82 fold by binding to poly(n-butylcyanoacrylate) nanoparticles coated with 1% nonionic surfactant polysorbate 80...
  40. ncbi Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis
    Theodore Tsai
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Vaccine 28:1877-80. 2010
    ..Further data will be forthcoming from planned post-licensure studies of adjuvanted H1N1 vaccines as they are distributed in the pandemic response...
  41. ncbi Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain
    Wangqiang Sun
    Nano Pharmaceutical Research Center and Department of Material Science and Engineering, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
    Biomaterials 25:3065-71. 2004
    ..Therefore, the specific role of T-80 coating on nanoparticles in brain targeting was confirmed...
  42. pmc Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
    Grazia Galli
    Translational Medicine, Novartis Vaccines, Siena, Italy 53100
    Proc Natl Acad Sci U S A 106:7962-7. 2009
    ..These results suggest that pre-pandemic vaccination strategies should be considered...
  43. ncbi Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats
    Alessandra Ambruosi
    Institut fur Pharmazeutische Technologie, Johann Wolfgang Goethe Universitat, Marie Curie Strabe 9, D 60439, Frankfurt am Main, Germany
    J Drug Target 13:535-42. 2005
    ..After longer time periods after injection the differences between the three preparations decreased...
  44. ncbi Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
    Filippo Ansaldi
    CIRI IV, Department of Health Sciences, University of Genoa, Genoa, Italy
    Vaccine 26:1525-9. 2008
    ..Thus, MF59-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations...
  45. ncbi Evaluation of developmental neurotoxicity of polysorbate 80 in rats
    Makoto Ema
    Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan
    Reprod Toxicol 25:89-99. 2008
    ..Histopathological examinations of the brain revealed no toxicological changes. Lowered body weight was observed in male and female offspring at 7.5%. The NOAEL in this study was considered to be 1.0% (1.864ml/mg/kgbw/day)...
  46. ncbi Analysis of phase diagram and microstructural transitions in an ethyl oleate/water/Tween 80/Span 20 microemulsion system using high-resolution ultrasonic spectroscopy
    Sinead Hickey
    School of Chemistry and Chemical Biology University College Dublin, Belfield, Dublin 4, Ireland
    Int J Pharm 388:213-22. 2010
    ....
  47. ncbi Food-grade microemulsions based on nonionic emulsifiers: media to enhance lycopene solubilization
    Aviram Spernath
    Casali Institute of Applied Chemistry and Department of Organic Chemistry, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Agric Food Chem 50:6917-22. 2002
    ..Structural aspects studied by self-diffusion NMR were correlated to the solubilization capacity, and transformational structural changes were identified...
  48. pmc Vaccine prevention of maternal cytomegalovirus infection
    Robert F Pass
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham 35233, USA
    N Engl J Med 360:1191-9. 2009
    ..Congenital infection with cytomegalovirus (CMV) is an important cause of hearing, cognitive, and motor impairments in newborns...
  49. ncbi Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients
    A de Roux
    Department of Chest and Infectious Diseases, Heckeshorn, Helios Kliniken Emil von Behring, Berlin, Germany
    Vaccine 24:1537-42. 2006
    ..Systemic steroids did not influence the antibody response towards the MF59-adjuvanted influenza vaccine. We found that the strains included in the vaccine showed varying long-term immunogenicity...
  50. ncbi Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier
    Jorg Kreuter
    Institut fur Pharmazeutische Technologie, Biozentrum, J W Goethe Universitat, Frankfurt, Germany
    J Drug Target 10:317-25. 2002
    ..Bound drugs then may be further transported into the brain by diffusion following release within the endothelial cells or, alternatively, by transcytosis...
  51. pmc Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution
    Renuka Thirumangalathu
    Process and Product Development Department, Formulation and Analytical Resources, Amgen, Inc, Thousand Oaks, California 91320, USA
    J Pharm Sci 98:3167-81. 2009
    ..A formulation strategy involving optimization of colloidal stability of the antibody as well as incorporation of surfactants such as polysorbate 20 is proposed to reduce silicone oil-induced aggregation of therapeutic protein products...
  52. ncbi Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
    ..001). MF59 significantly increased GMTs of antibody when compared to non-adjuvanted vaccine (P<0.001)...
  53. ncbi Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy
    Anna M Iorio
    Department of Hygiene, University of Perugia, Via del Giochetto, 06122 Perugia, Italy
    Vaccine 21:3629-37. 2003
    ....
  54. ncbi MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
    Audino Podda
    Chiron Vaccines Clinical Research and Medical Affairs, Siena, Italy
    Expert Rev Vaccines 2:197-203. 2003
    ..MF59 has been the first adjuvant to be licensed for human use after alum and, as part of an enhanced influenza vaccine for the elderly, is now available in the marketplace of several countries worldwide...
  55. ncbi Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways
    Bruce A Kerwin
    Department of Pharmaceutics, Amgen Inc, One Amgen Center Dr, Thousand Oaks, California 91320, USA
    J Pharm Sci 97:2924-35. 2008
    b>Polysorbates 20 and 80 (Tween 20 and Tween 80) are used in the formulation of biotherapeutic products for both preventing surface adsorption and as stabilizers against protein aggregation...
  56. ncbi Influence of an optimized non-ionic emulsifier blend on properties of oil-in-water emulsions
    R P Gullapalli
    Banner Pharmacaps Inc, High Point, NC, USA
    Eur J Pharm Biopharm 48:233-8. 1999
    ..This difference was attributed to the optimization of the emulsifier blend and processing parameters in the preparation of emulsions...
  57. ncbi Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
    K G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Lancet 357:1937-43. 2001
    ..We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety, tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines...
  58. ncbi An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
    Giuseppe Del Giudice
    Chiron Vaccines, Research Center and Clinical Research, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 24:3063-5. 2006
    ..We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine...
  59. ncbi Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study
    R N Alyautdin
    Department of Pharmacology, Sechenov Medical Academy, Moscow, Russia
    J Microencapsul 15:67-74. 1998
    ..Thus only the loading of tubocurarine onto the polysorbate 80-coated nanoparticles appears to enable the transport of this quaternary ammonium compound through the blood-brain barrier...
  60. ncbi Dual effects of Tween 80 on protein stability
    Wei Wang
    Pfizer Inc, Global Biologics, 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
    Int J Pharm 347:31-8. 2008
    ..Addition of 0.1% Tween 80 not only increased the rate of oxidation in general but also altered the temperature-dependency of IL-2 mutein oxidation...
  61. ncbi Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers
    Douglas K Mitchell
    Center for Pediatric Research, Children s Hospital of the King s Daughters, Eastern Virginia Medical School, Norfolk, VA, USA
    Pediatr Infect Dis J 21:133-8. 2002
    ..We conducted a Phase I trial in CMV-seronegative toddlers to evaluate the reactogenicity and immunogenicity of a CMV gB vaccine administered with MF59, an oil and water adjuvant...
  62. ncbi Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women
    C K Cunningham
    Department of Pediatrics, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA
    Clin Infect Dis 32:801-7. 2001
    ..Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants...
  63. ncbi The effects of Tween 20 and sucrose on the stability of anti-L-selectin during lyophilization and reconstitution
    L S Jones
    School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Pharm Sci 90:1466-77. 2001
    ..Potential mechanism(s) for the Tween 20 effects were investigated. However, no evidence of thermodynamic stabilization of anti-L-selectin conformation (e.g., by Tween 20 binding) could be detected...
  64. ncbi MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
    Paolo Durando
    Department of Health Sciences Section of Hygiene and Preventive Medicine, University of Genoa, Head of the Outpatient Clinic of the Hygiene Unit, San Martino University Hospital, Via Pastore 1 16132, Genoa, Italy
    Expert Opin Biol Ther 10:639-51. 2010
    ..The protection offered by non-adjuvanted vaccines may be further reduced by periodic antigenic drifts...
  65. ncbi Comparative enhancer effects of Span20 with Tween20 and Azone on the in vitro percutaneous penetration of compounds with different lipophilicities
    A Lopez
    Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Avd Vicente Andrés Estellés s n, 46100, Burjassot, Spain
    Int J Pharm 202:133-40. 2000
    ..The enhancer concentration must also be taken into account, even though the influence of the concentration seems to depend on the lipophilicity of the penetrant assayed...
  66. pmc Molecular and cellular signatures of human vaccine adjuvants
    F Mosca
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 105:10501-6. 2008
    ..We propose that oil-in-water emulsions are the most efficient human vaccine adjuvants, because they induce an early and strong immunocompetent environment at the injection site by targeting muscle cells...
  67. ncbi Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid
    A A Attama
    Institut fur Pharmazeutische Technologie, Technische Universität Carolo Wilhelmina zu Braunschweig, Mendelssohnstrasse 1, D 38106 Braunschweig, Germany
    Int J Pharm 334:179-89. 2007
    ..The result of this study also shows a method of improving natural lipids for use in particulate drug delivery systems...
  68. ncbi Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Clin Infect Dis 43:1135-42. 2006
    ..Influenza A/H9N2 viruses can infect humans and are considered to be a pandemic threat. Effective vaccines are needed for these and other avian influenza viruses...
  69. ncbi MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    D T O'Hagan
    Novartis Vaccines and Diagnostics Inc, Siena, Italy
    Clin Pharmacol Ther 82:740-4. 2007
    ..The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately...
  70. ncbi Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
    R Gasparini
    Institute of Hygiene, University of Siena, Italy
    Eur J Epidemiol 17:135-40. 2001
    ....
  71. pmc Improved dissolution of oleanolic acid with ternary solid dispersions
    Longxiao Liu
    College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China
    AAPS PharmSciTech 8:E113. 2007
    ..Moreover, the dissolution of ternary solid dispersion was faster compared with that of binary solid dispersion. Polysorbate 80 played an important positive role in dissolution of the solid dispersion...
  72. ncbi The preparation of pellets containing non-ionic surfactants by extrusion/spheronization
    F Podczeck
    Department of Mechanical Engineering, University College London, Torrington Place, London WC1E 7JE, UK
    Int J Pharm 361:33-40. 2008
    ..The maximum amount of the surfactant, which could be incorporated into the final pellet, however, was found to be approximately 22.5% for both the hydrophobic surfactants and 32.5% for the hydrophilic surfactant...
  73. ncbi Effects of surfactant characteristics on drug availability from suppositories
    N Realdon
    Department of Pharmaceutical Sciences, University of Padova, Italy
    Pharmazie 63:459-63. 2008
    ..Such interactions appear to greatly influence drug release from suppositories, which, in turn, is the main parameter determining drug availability...
  74. ncbi Some non-equilibrium phenomena in the malic acid/water/Polysorbate 81 system
    Abeer Al Bawab
    Chemistry Department, Faculty of Science, University of Jordan, P O Box 13536, Amman 11942, Jordan
    Int J Pharm 332:140-6. 2007
    ..In one case was observed a separated layer, which was not found in the phase diagram under equilibrium conditions...
  75. ncbi Study of deformation process of stored polymethacrylate free films
    J Bajdik
    University of Szeged, Department of Pharmaceutical Technology, Szeged, Hungary
    Pharmazie 61:887-8. 2006
    ..Increase of the storage time increased the changes in these parameters. The presence of polysorbate 80 in the films reduced the change in behaviour of the films at lower relative humidity...
  76. ncbi Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system
    Mauro Serratoni
    The School of Pharmacy, University of London, London, UK
    Eur J Pharm Biopharm 65:94-8. 2007
    ..Thus, the formulation approach offers the possibility of formulating and controlling the in vitro release of water-insoluble drugs from solid oral dosage forms...
  77. ncbi Fast-dissolving microparticles fail to show improved oral bioavailability
    S M Wong
    Department of Pharmaceutics, School of Pharmacy, London WC1N 1AX, UK
    J Pharm Pharmacol 58:1319-26. 2006
    ..The poor in-vivo performance of the bipyramidal particles showed that although the dissolution rate of a Class II drug is thought to be a good indicator of its in-vivo bioavailability, this is not always the case...
  78. ncbi Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid
    Soo Jeong Lim
    National Research Lab for Drug and Gene Delivery, College of Pharmacy, Researche Institute of Pharmaceutical Sciences, Seoul National University, San 56 1, Shinlim Dong, Kwanak gu, Seoul 151 742, South Korea
    Int J Pharm 243:135-46. 2002
    ..Taken together, SLN formulation of ATRA with similar characteristics to those of parenteral emulsions could be obtained even after freeze-drying...
  79. ncbi Melt granulation using a twin-screw extruder: a case study
    Barbara Van Melkebeke
    Laboratory of Pharmaceutical Technology, Ghent University, Harelbekestraat 72, B 9000 Ghent, Belgium
    Int J Pharm 326:89-93. 2006
    ..X-ray diffractograms showed distinct peaks of crystalline drug, the crystallinity of the drug did not change after 50 days, independent of the storage conditions...
  80. ncbi Water-Tween 40/Imwitor 308-isopropyl myristate microemulsions as delivery systems for ketoprofen: small-angle X-ray scattering study
    Matija Tomsic
    University of Ljubljana, Faculty of Chemistry and Chemical Technology, Askerceva 5, SI 1000 Ljubljana, Slovenia
    Int J Pharm 327:170-7. 2006
    ..Interestingly, all these changes in the inner structuration of the studied systems did not affect the trend of the drug release rates in this regime of water concentrations...
  81. ncbi Increased dissolution and physical stability of micronized nifedipine particles encapsulated with a biocompatible polymer and surfactants in a wet ball milling process
    Ning Li
    College of Pharmacy, University of Louisiana at Monroe, USA
    Pharmazie 61:595-603. 2006
    ....
  82. ncbi Preparation and characterization of a new lipid nano-emulsion containing two cosurfactants, sodium palmitate for droplet size reduction and sucrose palmitate for stability enhancement
    Shigehiko Takegami
    Kyoto Pharmaceutical University, Kyoto, Japan
    Chem Pharm Bull (Tokyo) 56:1097-102. 2008
    ..Slight formation of flocculation in the LNEs depending on the storage period was suggested by measurement of the 31P nuclear magnetic resonance line width of the LNEs...
  83. ncbi A rheological method to evaluate the physical stability of highly viscous pharmaceutical oil-in-water emulsions
    Houda Masmoudi
    Lab GOAE, CNRS UMR 6171, service 451, Universite Paul Cezanne Aix Marseille III, Avenue Escadrille Normandie Niemen 13397, Marseille Cedex 20, France
    Pharm Res 23:1937-47. 2006
    ..The influence of the type of oil and the type of emulsifier on the microstructure of the emulsions was also studied...
  84. pmc Dissolution improvement of high drug-loaded solid dispersion
    Siriporn Okonogi
    Faculty of Pharmacy, Department of Pharmaceutical Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand
    AAPS PharmSciTech 7:E52. 2006
    ..This was because of polysorbate 80, which improved wettability and solubilized the non-molecularly dispersed or crystalline fraction of OFX...
  85. ncbi The preparation of pellets containing a surfactant or a mixture of mono- and di-gylcerides by extrusion/spheronization
    John Michael Newton
    The School of Pharmacy, University of London, Brunswick Square, London WC1N 1AX, UK
    Eur J Pharm Sci 30:333-42. 2007
    ..The ability to use the materials independently offers further alternatives for the formulation of water insoluble drugs into pellet formulations...
  86. ncbi Effect of emulsifier on oxidation properties of fish oil-based structured lipid emulsions
    Lydia B Fomuso
    Department of Food Science and Technology, Food Science Building, The University of Georgia, Athens, Georgia 30602 7610, USA
    J Agric Food Chem 50:2957-61. 2002
    ..25% emulsifier concentration generally having a higher oxidation rate than 1% emulsifier concentration. Overall, oxidation did not progress significantly enough in 48 days of storage to affect DHA and EPA levels in the emulsion...
  87. ncbi Formulation and biopharmaceutical evaluation of silymarin using SMEDDS
    Jong Soo Woo
    Pharmaceutical Research Lab Hanmi Pharm Co, Hwaseong 445 913, Korea
    Arch Pharm Res 30:82-9. 2007
    ..5 times higher than that from the reference capsule. After its oral administration to rats, the bioavailability of the drug from the SMEDDS was 3.6 times higher than the reference capsule...
  88. ncbi Some considerations about the hydrophilic-lipophilic balance system
    Ricardo C Pasquali
    Cátedra de Farmacotecnia I, Departamento de Tecnologia Farmacêutica, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junin 956, 6o piso, 1113 Buenos Aires, Argentina
    Int J Pharm 356:44-51. 2008
    ..The HLB and required HLB values published by Griffin should only be taken as approximate guidelines...
  89. ncbi Caffeine-loaded niosomes: characterization and in vitro release studies
    Payam Khazaeli
    Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, and Pharmaceutical Technology Research Center, Kerman University of Medical Sciences, Kerman, Iran
    Drug Deliv 14:447-52. 2007
    ..High encapsulation efficiency, appropriate size distribution, and good vesicular stability, especially in solid state niosomes, make this type of vesicular systems a good alternative to liposomes for topical delivery of caffeine...
  90. ncbi Microemulsions--modern colloidal carrier for dermal and transdermal drug delivery
    Sandra Heuschkel
    Faculty of Biosciences, Institute for Pharmacy, Pharmaceutics and Biopharmaceutics, Martin Luther University Halle Wittenberg, Wolfgang Langenbeck Str 4, 06120 Halle Saale, Germany
    J Pharm Sci 97:603-31. 2008
    ..However, an extended use in practice depends on the choice of well-tolerated ingredients, mainly surfactants, and the restriction of their amounts in order to guarantee skin compatibility...
  91. ncbi Analysis of Tween based microemulsion in the presence of TB drug rifampicin
    S K Mehta
    Department of Chemistry and Center of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India
    Colloids Surf B Biointerfaces 60:95-104. 2007
    ..In addition, the particle size analysis indicates that the microemulsion changes into o/w emulsion at infinite dilution. Dissolution studies infer that a controlled release of rifampicin is expected from o/w emulsion droplet...
  92. ncbi Formulation of a cosurfactant-free O/W microemulsion using nonionic surfactant mixtures
    Y H Cho
    Department of Biotechnology, Yonsei University, Seoul, 120 749, South Korea
    J Food Sci 73:E115-21. 2008
    ..Dilution with a different aqueous medium, either water or acidic fluid, did not significantly change the microemulsion turbidity. DHA oil incorporated in microemulsion showed higher oxidation stability than free DHA oil...
  93. ncbi A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20
    Serena D Webb
    Department of Chemical Engineering, Center for Pharmaceutical Biotechnology, University of Colorado, Engineering Center, Room ECCH 111, Boulder, Colorado 80309 0424, USA
    J Pharm Sci 91:543-58. 2002
    ..Slowing the dissolution rates of lyophilized powders allows more time for the protein to refold while it decreases the maximum concentration of the protein at the dissolution interface, thus reducing the total amount of aggregation...
  94. ncbi Incorporation of antitubercular drug isoniazid in pharmaceutically accepted microemulsion: effect on microstructure and physical parameters
    S K Mehta
    Department of Chemistry and Center of Advanced Studies in Chemistry, Panjab University, Chandigarh, India
    Pharm Res 25:227-36. 2008
    ..The purpose of present study is to formulate microemulsion composed of oleic acid, phosphate buffer, Tween 80, ethanol and to investigate its potential as drug delivery system for an antitubercular drug isoniazid...
  95. ncbi Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Colloids Surf B Biointerfaces 65:98-105. 2008
    ..It is shown that oil-in-water emulsions using animal-derived components can be substituted with synthetic or plant-derived materials while still exhibiting satisfactory physicochemical and biological properties...
  96. ncbi Short communication: in vivo evaluation of microemulsion system for oral and parenteral delivery of rutaecarpine to rats
    Chul Soon Yong
    College of Pharmacy, Yeungnam University, Dae Dong, Gyongsan, South Korea
    Drug Dev Ind Pharm 33:531-4. 2007
    ..Thus, our results indicated that the microemulsion system composed of castor oil, polyethylene glycol 400, Tween 80, and water could be a more effective oral and parenteral dosage form for rutaecarpine...
  97. ncbi In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets
    Tetsuo Hayashi
    Life Science Institute, SSP Co, Ltd, Nanpeidai 1143, Narita shi, Chiba 286 1511, Japan
    Int J Pharm 341:105-13. 2007
    ..It is concluded that, the cluster tablets A developed in this study showed significantly less inter-subject variation of theophylline plasma levels than the conventional matrix tablets B...
  98. ncbi Stability of vitamins C and E in topical microemulsions for combined antioxidant therapy
    Branka Rozman
    Faculty of Pharmacy, University of Ljubljana, Askerceva, SI Slovenia
    Drug Deliv 14:235-45. 2007
    ....
  99. ncbi Fabrication of nano-fibrous collagen microspheres for protein delivery and effects of photochemical crosslinking on release kinetics
    O C M Chan
    Medical Engineering, Department of Mechanical Engineering, The University of Hong Kong, Pokfulam Road, Hong Kong Special Administrative Region, China
    J Control Release 129:135-43. 2008
    ..In summary, this study reports a novel collagen microsphere-based protein delivery system and demonstrates the possibility to use photochemical crosslinking as the secondary retention mechanism for proteins...
  100. ncbi Towards a molecular characterization of pharmaceutical excipients: mass spectrometric studies of ethoxylated surfactants
    Klaus Raith
    Martin Luther University Halle Wittenberg, Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, W Langenbeck Str, D 06120 Halle S, Germany
    Int J Pharm 319:1-12. 2006
    ..g. for identification of acyl chains. The work is intended to serve as a reference for mass spectrometric characterization of surfactants in the course of R&D, validation or change control...
  101. ncbi Bicontinuous water-AOT/Tween85-isopropyl myristate microemulsion: a new vehicle for transdermal delivery of cyclosporin A
    Hongzhuo Liu
    School of Pharmaceutics, Pharmaceutical University of Shenyang, Shenyang 110016, People s Republic of China
    Drug Dev Ind Pharm 32:549-57. 2006
    ..The increased transdermal delivery was found to be due mainly to water concentration and appeared to be dependent on the structure of the microemulsions...

Research Grants30

  1. Pediatric Acceptable Formulation of Amiodarone
    John Somberg; Fiscal Year: 2009
    ..At the successful completion of the pre-clinical studies, a bioequivalence study in adults would be requisite for FDA approval based on a Special Protocol Assessment granted by FDA. ..
  2. Peptide Profiling Techniques to Detect Thyroid Carcinoma
    Paul Tempst; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  3. Identification of secreted proteins important for tularemia pathogenesis
    Martin Pavelka; Fiscal Year: 2007
    ..Because of F. tularensis is a select agent and could be used a biological weapon, this research could potentially have a significant impact on public health in the future. [unreadable] [unreadable] [unreadable]..
  4. FUNCTIONAL STUDIES OF OSTEOBLASTS
    CAROL GAY; Fiscal Year: 2005
    ..g. mutations) in NCX can be predicted to result in an undermineralized skeleton. These studies will disclose novel mechanisms by which bone forming cells carry out mineralization of the extracellular matrix. ..
  5. A screen for small molecule inhibitors of soluble Abeta oligomer assembly
    Harry LeVine; Fiscal Year: 2007
    ..Anti-oligomer compounds could potentially block the cognitive impairment symptoms that oligomers elicit in animal models and interfere with the progression of Alzheimer's disease. [unreadable] [unreadable] [unreadable]..
  6. Development of genetic tools for Francisella tularensis
    Martin Pavelka; Fiscal Year: 2004
    ..The further development of Francisella genetics is timely, as the sequencing of the genome of the F. tularensis subsp. tularensis, strain Schu 4 is almost complete. ..
  7. BIOSYNTHESIS OF THE MYCOBACTERIAL PEPTIDOGLYCAN
    Martin Pavelka; Fiscal Year: 2004
    ..For the aims of this proposal, the Pi will study M. tuberculosis and M. smegmatis as a model organism using the techniques of classical bacterial genetics, molecular biology and biochemistry. ..
  8. Fourth International Conf. on Relaxin & Related Peptides
    ORRIN SHERWOOD; Fiscal Year: 2004
    ..Conference web site: http://www.life.uiuc.edu/relaxin2004/ ..
  9. Hormonal Regulation of the Cervix During Pregnancy
    ORRIN SHERWOOD; Fiscal Year: 2006
    ..Treatment with RU 486 alone and in combination with exogenous relaxin will be done at term with relaxin-deficient rats. ..
  10. PEGylated Prolactin Receptor Antagonists as Cancer Drugs
    MERRY SHERMAN; Fiscal Year: 2002
    ..Tumor growth or shrinkage will be monitored non-invasively, using tumors derived from cells transfected to contain luciferase, in collaboration with Robert S. Negrin...
  11. Genetic screens to identify mycobacterial porins
    Martin Pavelka; Fiscal Year: 2008
    ..This would be an important contribution to reduce the public health burden of mycobacterial disease in the United States. [unreadable] [unreadable] [unreadable]..
  12. 3D ELECTRON MICROSCOPY OF PYRUVATE DEHYDROGENASE
    JAMES STOOPS; Fiscal Year: 2002
    ..A 3-D reconstruction of the beef kidney intact PDC will permit a comparison of the mammalian and yeast complexes. ..
  13. PHASE IB TRIAL OF CYTOMEGALOVIRUS GLYCOPROTEIN B VACCINE
    Paul Griffiths; Fiscal Year: 2008
    ..If a vaccine schedule can be identified which controls viral load, this will be recommended for a phase II placebo-controlled trial of clinical efficacy. ..
  14. QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT VACCINE IN HUMANS
    Ranjit Ray; Fiscal Year: 2009
    ..Our proposed complimentary experimental approaches in this vaccinated cohort will help in developing successful vaccine strategies for the intervention of the first crucial step of the HCV life cycle. ..
  15. Chamomile as Medicine for Prostate cancer
    Sanjay Gupta; Fiscal Year: 2009
    ..Completion of the proposed studies will provide a 'head start'to initiate clinical trials in prostate cancer patients and/or high-risk individuals. ..
  16. Role of Mouse Allergen in Childhood Asthma
    Wanda Phipatanakul; Fiscal Year: 2007
    ..This will help her translate knowledge gained from her research into direct community benefit. [unreadable] [unreadable]..
  17. Phospholipases in the Pathogenesis of M. tuberculosis
    Sarah Parker; Fiscal Year: 2006
    ..Dr. Parker is committed to research in M. tuberculosis, and it holds a special significance to her because of her life experiences. ..
  18. Subharmonic Microbubble Signals for Pressure Estimation
    Flemming Forsberg; Fiscal Year: 2008
    ..This will allow potentially life-threatening diseases, such as increased pressure in the liver, to be diagnosed early. [unreadable] [unreadable] [unreadable]..
  19. Exposure Intervention in a Rural Pediatric Asthma Cohort
    Peter Thorne; Fiscal Year: 2005
    ..Detailed health and home hygiene questionnaires and home inspections will be conducted at baseline and one year later, as will child spirometry. ..
  20. High Resolution Cryo-Electron Microscope
    JAMES STOOPS; Fiscal Year: 2002
    ..The identification of seven secondary users shows that there is major interest in the larger medical school community that may greatly benefit by acquisition of the high-resolution electron microscope...
  21. Alphavirus Replicons for Mucosal HIV Vaccines
    Michael Vajdy; Fiscal Year: 2002
    ....
  22. Prostate Cancer Chemoprevention by Apigenin
    Sanjay Gupta; Fiscal Year: 2003
    ..These studies could be considered as a starting point for an expanded program for the development of apigenin as a promising agent against CaP in humans. ..
  23. HCV ENVELOPE GLYCOPROTEINS AND VACCINE DEVELOPMENT
    Ranjit Ray; Fiscal Year: 2003
    ....
  24. Inhibition of Prostate Carcinogenesis by Apigenin
    Sanjay Gupta; Fiscal Year: 2003
    ..A successful completion of this application will set a platform to define the role of apigenin as a promising agent against prevention and possibly therapy of prostate cancer in humans. ..
  25. Contrast-Enhanced Ultrasound Detection of Angiogenesis
    Flemming Forsberg; Fiscal Year: 2004
    ..If successful, this project will permit non-invasive ultrasound evaluations of anti-angiogenic tumor therapies in animals as well as humans. ..
  26. Anti-proliferative Effects of D-limonene against Prosta*
    Sanjay Gupta; Fiscal Year: 2005
    ..Successful completion of this application will establish the cancer chemopreventive and/or therapeutic potential of D-limonene against prostate cancer and mechanisms involved with its anti-proliferative response. ..
  27. Functional Activities of HCV Core Protein
    Ranjit Ray; Fiscal Year: 2005
    ....
  28. Reactivation of GSTP1 Gene by Green Tea Polyphenols
    Sanjay Gupta; Fiscal Year: 2005
    ..abstract_text> ..
  29. 3D ELECTRON MICROSCOPY OF PYRUVATE DEHYDROGENASE
    JAMES STOOPS; Fiscal Year: 2001
    ..A 3-D reconstruction of the beef kidney intact PDC will permit a comparison of the mammalian and yeast complexes. ..